细胞生物学
化学
体内
细胞因子
细胞毒性T细胞
白细胞介素3
分子生物学
T细胞
嵌合抗原受体
受体
白细胞介素2受体
体外
生物
白细胞介素21
T淋巴细胞
白细胞介素12
抗原提呈细胞
作者
Travis J. Friesen,Alyssa Sheih,Nikole Perdue,Nolan G. Ericson,Dillon K. Jarrell,Ashley M. Yingst,Christopher J. Nicolai,Timothy Gervascio,Seungjin Shin,Jessica Freeman,Laurie Beitz,Samantha D. O’Hara,Alessandra M. Sullivan,Alissa Brandes,Ryan P. Larson,Jeffrey J Teoh
标识
DOI:10.1016/j.ymthe.2026.08.003
摘要
Ex vivo-manufactured chimeric antigen receptor (CAR) T cells targeting CD19 have transformed treatment strategies for patients with B cell malignancies and have shown promising results in autoimmune disease. Yet despite their success, significant barriers remain that impede patient access to these therapies, including their complex manufacturing and the need for lymphodepleting chemotherapy. Moreover, many patients who receive ex vivo-manufactured CD19 CAR T cells do not achieve durable responses, suggesting that the expansion and persistence of CAR T cells may need improvement, and/or that strategies targeting alternative antigens may be needed for patients who are refractory to or relapse following treatment with CD19-directed therapies. Umoja is developing a surface-engineered lentiviral vector platform capable of generating CAR T cells in vivo without lymphodepletion. UB-VV400 delivers a payload composed of a fully human anti-CD22 CAR and the rapamycin-activated cytokine receptor (RACR), which enable preferential expansion and enrichment of CAR T cells in response to rapamycin. Here, we describe preclinical studies demonstrating that UB-VV400 generates anti-CD22 CAR T cells that kill CD22-expressing B cells and tumor cells in vitro and in vivo, and that engagement of RACR results in the selective expansion and enrichment of CAR T cells in vivo leading to complete tumor clearance and B cell depletion.
科研通智能强力驱动
Strongly Powered by AbleSci AI